The different antitumor and other biological effects of the third-generation antitumor platinum drug oxaliplatin [(1R,2R-diamminocyclohexane)oxalatoplatinum(II)] in comparison with those of conventional cisplatin [cis-diamminedichloridoplatinum(II)] are often explained by the ability of oxaliplatin to form DNA adducts of different conformation and consequently to exhibit different cytotoxic effects. This work describes, for the first time, the structural and biochemical characteristics of the interstrand cross-links of oxaliplatin. We find that: 1) DNA bending, unwinding, thermal destabilization, and delocalization of the conformational alteration induced by the cross-link of oxaliplatin are greater than those observed with the cross-link of cisplatin; 2) the affinity of high-mobility-group proteins (which are known to mediate the antitumor activity of platinum complexes) for the interstrand cross-links of oxaliplatin is markedly lower than for those of cisplatin; and 3) the chirality at the carrier 1,2-diaminocyclohexane ligand can affect some important structural properties of the interstrand cross-links of cisplatin analogues. Thus, the information contained in the present work is also useful for a better understanding of how the stereochemistry of the carrier amine ligands of cisplatin analogues can modulate their anticancer and mutagenic properties. The significance of this study is also reinforced by the fact that, in general, interstrand cross-links formed by various compounds of biological significance result in greater cytotoxicity than is expected for monofunctional adducts or other intrastrand DNA lesions. Therefore, we suggest that the unique properties of the interstrand cross-links of oxaliplatin are at least partly responsible for this drug's unique antitumor effects.

Download full-text PDF

Source
http://dx.doi.org/10.1002/chem.200701352DOI Listing

Publication Analysis

Top Keywords

interstrand cross-links
24
cross-links oxaliplatin
12
unique properties
8
chirality carrier
8
properties interstrand
8
cisplatin analogues
8
oxaliplatin
7
interstrand
6
cross-links
6
antitumor
5

Similar Publications

A Photoinducible DNA Cross-Linking Agent with Potent Cytotoxicity and Selectivity Toward Triple-Negative Breast Cancer Cell Line.

Chem Res Toxicol

December 2024

Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.

DNA interstrand cross-links (ICLs) are the sources of the cytotoxicity of many anticancer agents. Selenium compounds showed great potential as anticancer drugs. In this work, we synthesized a binaphthalene analog containing phenyl selenide (-SePh) as the leaving group and investigated its photochemical reactivity toward DNA as well as its cytotoxicity and selectivity.

View Article and Find Full Text PDF
Article Synopsis
  • Acquired resistance to temozolomide (TMZ) in glioblastoma patients, particularly those with DNA mismatch repair deficiencies, limits treatment effectiveness, prompting research into the new drug KL-50, which targets cancer cells in an MMR-independent manner.
  • In studies, KL-50 significantly improved the median survival of mice with both naive and post-TMZ glioblastoma xenografts, showcasing its potential as a superior treatment option.
  • Results indicate KL-50 may be particularly effective in MGMT and MMR-deficient tumors, offering hope for better management of recurrent glioblastoma after initial TMZ therapy.
View Article and Find Full Text PDF

Exposure to ultraviolet radiation, which leads to the formation of mutagenic and cytotoxic DNA lesions such as cyclobutane pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4 PPs), can be potentially fatal. The way UVA forms DNA lesions and alters DNA topology and mechanics is still unclear, unlike the cases of UVC and UVB. Herein, Atomic Force Microscopy (AFM) and AFM-based Force Spectroscopy (AFS) have been employed to investigate the topological and mechanical properties of single DNA molecules, bare or E.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research has expanded the concept of "FA signaling" to include over 30 proteins involved in DNA Damage Response (DDR), making it the largest cellular defense network against DNA damage.
  • Different human cancers display unique mutational profiles related to DDR/FA signaling, with ATM and BRCA2 being major players across many cancer types, while genes like FANCT predominate in breast and liver cancers.
  • Understanding these mutation patterns is crucial, as they greatly influence patient survival and treatment outcomes, potentially guiding more effective therapeutic strategies for various cancers.
View Article and Find Full Text PDF

The splicing factor CCAR1 regulates the Fanconi anemia/BRCA pathway.

Mol Cell

July 2024

Division of Radiation and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA. Electronic address:

The twenty-three Fanconi anemia (FA) proteins cooperate in the FA/BRCA pathway to repair DNA interstrand cross-links (ICLs). The cell division cycle and apoptosis regulator 1 (CCAR1) protein is also a regulator of ICL repair, though its possible function in the FA/BRCA pathway remains unknown. Here, we demonstrate that CCAR1 plays a unique upstream role in the FA/BRCA pathway and is required for FANCA protein expression in human cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!